New study tracks quality of life in myeloma patients on selinexor combo
NCT ID NCT05954780
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 37 times
Summary
This observational study follows 75 people with relapsed or refractory multiple myeloma who are already taking selinexor combined with bortezomib and dexamethasone. Researchers will track quality of life, side effects, and how the treatment works in everyday medical practice. The goal is to provide real-world evidence that complements earlier clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Gemeinschaftspraxis für Hämatologie und Onkologie GbR
Ravensburg, Baden-Wurttemberg, 88212, Germany
-
Medizinische Universität Wien, Universitätsklinik für Innere Medizin I
Vienna, 1090, Austria
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
selinexor (Nexpovio®) combined with bortezomib and dexamethasone
What this could lead to
If successful, this study could provide doctors with better information on how to manage side effects and improve quality of life for people with multiple myeloma.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove the treatment works better than other options. Results may vary widely among participants.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.